Recombinant Human CEACAM7 protein

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The carcinoembryonic antigen-related cell adhesion molecule 7 (CEACAM7) also known by its gene name BAC2 is a glycosylated protein that has an approximate mass of 29 kDa. CEACAM7 belongs to the CEA family of proteins which are part of the immunoglobulin superfamily. This protein is mainly expressed on epithelial cells particularly in colon and rectum tissues as well as in normal and cancerous tissues of the colon epithelium. Expression is often downregulated in malignant transformation indicating alterations during cancer progression.

Biological function summary

The role of CEACAM7 involves cell adhesion processes and intercellular signaling. It functions as a calcium-independent cell adhesion molecule by mediating homophilic binding contributing to the maintenance of tissue architecture and stability. Although CEACAM7 does not typically form complexes with other proteins its interactions are critical for maintaining epithelial cell integrity. These interactions affect how cells communicate and can influence cell growth and differentiation.

Pathways

CEACAM7 is involved in regulating cell adhesion and immune response pathways. The protein contributes to the homophilic intercellular adhesion mediated by other members of the CEACAM family such as CEACAM1 and CEACAM6. These interactions scaffold the communication between cells affecting both adhesion and immune response mechanisms. Although the protein’s role in the pathways is not as well-characterized as other family members its alteration can influence downstream effects making it an interesting target for further pathway analysis.

CEACAM7 alterations have associations with colorectal cancer and inflammatory bowel disease (IBD). In colorectal cancer the downregulation of CEACAM7 correlates with tumor progression and poor prognosis whereas in IBD its expression might contribute towards the dysregulation of epithelial barriers. Through these conditions interactions with CEACAM1 and CEACAM6 signify how changes in the CEACAM family can have broader impacts on disease progression and manifestation. Understanding these interactions opens potential avenues for therapeutic intervention targeting CEACAM7 in related conditions.